MMHD [(S,E)-2-methyl-1-(2-methylthiazol-4-yl) hexa-1,5-dien-ol], a novel synthetic compound derived from epothilone, suppresses nuclear factor-κB-mediated cytokine expression in lipopolysaccharide-stimulated BV-2 microglia

Journal of Pharmacological Sciences

Volumn 112, Issue 2, 2010, Pages 158-166

  Jeon, Na Ra ^a   Koppula, Sushruta ^a   Kim, Byung Wook ^a   Park, Su Ho ^b   Lee, Hyo Won ^b   Choi, Dong Kug ^a  

^a Konkuk University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

Lipopolysaccharide; Microglia; MMHD (S, E ) 2 methyl 1 (2 methylthiazol 4 yl) hexa 1,5 dien ol ; Neurodegenerative disease; Nuclear factor B (NF B)

Indexed keywords

2 METHYL 1 (2 METHYLTHIAZOL 4 YL) HEXA 1,5 DIEN OL; CYCLOOXYGENASE 2; EPOTHILONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL VIABILITY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSLOCATION; IMMUNOFLUORESCENCE; MICROGLIA; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 77249093670     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09239FP     Document Type: Article

References (45)

1. Perry VH, Gordon S. Macrophages and microglia in the nervous system. Trends Neurosci. 1988;11:273-277.
2. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38: 1285-1291.
3. Nelson PT, Soma LA, Lavi E. Microglia in diseases of the central nervous system. Ann Med. 2002;34:491-500.
4. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington's disease. Brain Res Bull. 2007;72:148-151.
5. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol. 1992;149:2736-2741.
6. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288:335-339.
7. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci. 2002;16:2103-2112.
8. Kang KM, Lee GS, Lee JH, Choi IW, Shin DW, Lee YH. Effects of iNOS inhibitor on IFN-gamma production and apoptosis of splenocytes in genetically different strains of mice infected with Toxoplasma gondii . Korean J Parasitol. 2004;42:175-183.
9. Shao DZ, Lin M. Platonin inhibits LPS-induced NF-kappaB by preventing activation of Akt and IKKbeta in human PBMC. Inflamm Res. 2008;57:601-606.
10. Dawson TM, Dawson VL, Snyder SH. Molecular mechanisms of nitric oxide actions in the brain. Ann N Y Acad Sci. 1994;738:76-85.
11. Boulet I, Ralph S, Stanley E, Lock P, Dunn AR, Green SP, et al. Lipopolysaccharide- and interferon-gamma-induced expression of hck and lyn tyrosine kinases in murine bone marrow-derived macrophages. Oncogene. 1992;7:703-710.
12. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci. 1998;18:1633-1641.
13. Chen CC, Wang JK, Chen WC, Lin SB. Protein kinase C eta mediates lipopolysaccharide-induced nitric-oxide synthase expression in primary astrocytes. J Biol Chem. 1998;273: 19424-19430.
14. Minghetti L, Levi G. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol. 1998;54:99-125.
15. Simon LS. Actions and toxicity of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 1996;8:169-175.
16. Bauer MK, Lieb K, Schulze-Osthoff K, Berger M, Gebicke-Haerter PJ, Bauer J, et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem. 1997;243:726-731.
17. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12: 1005-1015.
18. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res. 2009;34:55-65.
19. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res. 1995;55:2325-2333.
20. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science. 2004;305:866-869.
21. Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol. 2009;11:158-166.
22. Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res. 2005;11:6950-6958.
23. Hoffmann J, Iduna F, Ulrich K. ZK-EPO, a potent third-generation epothilone, is effective in models of breast cancer metastasis. Proc Am Assoc Cancer Res. 2006;45:7942-7948.
24. Dietzmann A, Kanakis D, Kirches E, Kropf S, Mawrin C, Dietzmann K. Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton. J Neurooncol. 2003;65:99-106.
25. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Ann Biochem. 1982;126:131-138.
26. Bredenkamp MW, Holzapfel CW. The chiral synthesis of thiazole amino acid enantiomers. Syn Commun. 1990; 20:2235-2249.
27. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996; 271:33157-33160.
28. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med. 1993;177:1779-1784.
29. Adams V, Nehrhoff B, Späte U, Linke A, Schulze PC, Baur A, et al. Induction of iNOS expression in skeletal muscle by IL-1β and NF-κB activation: an in vitro and in vivo study. Cardiovasc Res. 2002;54:95-104.
30. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signaling. 2001;13:85-94.
31. Mukaida N, Ishikawa Y, Ikeda N, Fujioka N, Watanabe S, Kuno K, et al. Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cellfree system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. J Leukoc Biol. 1996;59:145-151.
32. Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem. 2001;130: 169-175.
33. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57-69.
34. Klegeris A, McGeer EG., McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol. 2007;20:351-357.
35. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol. 2007;205:295-312.
36. McGeer EG, McGeer PL. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs. 2007;21:789-797.
37. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol. 2005;175:4320-4330.
38. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling. Nat Rev Immunol. 2007;7:353-364.
39. Ozato K, Tsujimura H, Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques. 2002;Suppl:66-68, 70, 72 passim.
40. McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. Microglia in degenerative neurological disease. Glia. 1993;7:84-92.
41. Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis. 1999;179 Suppl 2:S294-S304.
42. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol. 1998;17:217-228.
43. Nicholas RS, Wing MG, Compston A. Nonactivated microglia promote oligodendrocyte precursor survival and maturation through the transcription factor NF-kappa B. Eur J Neurosci. 2001;13:959-967.
44. Petrova TV, Akama KT, Van Eldik LJ. Selective modulation of BV-2 microglial activation by prostaglandin E(2). Differential effects on endotoxin-stimulated cytokine induction. J Biol Chem. 1999;274:28823-28827.
45. Ye SM, Johnson RW. Regulation of interleukin-6 gene expression in brain of aged mice by nuclear factor kappaB. J Neuroimmunol. 2001;117:87-96.